NBIX — NEUROCRINE BIOSCIENCES INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 914475 ·
Last close
$165.92
Market Cap
$16.79B
52W High
$186.12
52W Low
$122.14
ADV30
1,382,547
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 959,000,000 | 935,800,000 | 153,000,000 | 144,400,000 | 5,359,100,000 | 332,400,000 | 1,665,500,000 |
| Mar 2026 | 814,500,000 | 800,700,000 | 186,000,000 | 197,900,000 | 4,906,200,000 | 266,500,000 | 1,498,800,000 |
| Dec 2025 | 805,500,000 | 787,900,000 | 227,900,000 | 153,700,000 | 4,631,500,000 | 713,000,000 | 1,378,400,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,065,800,000
Investing CF
$-705,600,000
Financing CF
$-60,400,000
CapEx
$-41,700,000
Dividends Paid
—
Buybacks
$-158,100,000
EPS Diluted TTM
$6.74
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$838,400,000
Inventory
$66,100,000
Receivables
$957,300,000
ST Investments
$96,400,000
EBIT TTM
$863,000,000
Pretax Income TTM
$932,100,000
Interest Exp TTM
$3,200,000
Analysts
28
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,701,700,096
EBITDA
$1,069,100,032
Free Cash Flow
$1,018,237,504
Enterprise Value
$16,377,525,248
Total Cash
$737,900,032
Total Debt
$451,800,000
Shares Out
101,218,643
Trailing EPS
$6.74
Book Value
$38.29
ROE
20.4%
ROA
12.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,860,500,000 | 636,500,000 | 478,600,000 | 4,631,500,000 | 1,378,400,000 | 3,253,100,000 | 782,700,000 |
| Dec 2024 | 2,355,300,000 | 583,000,000 | 341,300,000 | 3,718,700,000 | 1,129,000,000 | 2,589,700,000 | 595,400,000 |
| Dec 2023 | 1,887,100,000 | 394,800,000 | 249,700,000 | 3,251,400,000 | 1,019,400,000 | 2,232,000,000 | 389,900,000 |
| Dec 2022 | 1,488,700,000 | 249,000,000 | 154,500,000 | 2,368,700,000 | 660,900,000 | 1,707,800,000 | 339,400,000 |
TTM Snapshot
Revenues TTM
$3,373,900,000
NetIncome TTM
$705,500,000
OpCashFlow TTM
—
Assets (Latest)
$5,359,100,000
Forward EPS
$12.09
Max Pain — expiry 2027-12-17
max pain strike: $145.00 · spot: $162.86 · call oi: 6,113 · put oi: 82
Expected Move to 2027-12-17:
±$61.54
(37.79%) —
implied range
$101.32 –
$224.40
· ATM straddle on $165.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | $16.71B | $68.50 | — |
| BNTX | BioNTech SE | $21.32B | $84.86 | — |
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
News headlines (Yahoo Finance, 1h cache)
Neurocrine Biosciences (NBIX) Stock Still Looks Undervalued As Its 89% Run Draws Focus
2026-11-18 10:13 · Yahoo
Should You Buy Neurocrine Biosciences Stock For Its Cash?
2026-11-16 11:42 · Yahoo
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
2026-11-10 21:01 · Yahoo
NBIX or GRDN: Which Is the Better Value Stock Right Now?
2026-11-10 19:38 · Yahoo
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
2026-11-09 16:45 · Yahoo
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
2026-11-09 16:00 · Yahoo
NBIX vs. GRDN: Which Stock Is the Better Value Option?
2026-11-09 15:40 · Yahoo
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
2026-11-09 13:55 · Yahoo
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
2026-11-05 13:30 · Yahoo
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
2026-11-03 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.